Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1055)
  3. Book Section (64)
  4. Review (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2694)
  2. Department of Medicine (2694)
  3. Hematologic Malignancies, Division of (2694)
  4. Population Sciences Research Program (742)
  5. Survivorship Research (654)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (781)
  2. Steven Horwitz (664)
  3. Maria Palomba (443)
  4. Ariela Noy (369)
  5. David Straus (360)
  6. Alison Moskowitz (355)

More People

Years
  1. 2025 (41)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (875)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. British Journal of Haematology (81)
  5. Leukemia and Lymphoma (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (940)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2694)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PROPEL: A multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B(12) and folic acid supplementation in patients with replapsed or refractory peripheral T-cell lymphoma
    Meeting Abstract

    O'Connor, O. A.; Pro, B.; Pinter-Brown, L.; Popplewell, L.; Barlett, N.; Shustov, A.; Lechowicz, M. J.; Savage, K. J.; Coiffier, B.; Jacobsen, E.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P.; Moskowitz, C.; Portlock, C.; Sarasohn, D.; Dumitrescu, O.; Neylon, E.; Patterson, M.; Zelenetz, A.; Saunders, M.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Normalization of FDG-PET pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma - Memorial Sloan Kettering protocol 04-047
    Meeting Abstract

    Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; Portlock, C. S.; Straus, D. J.; Gerecitano, J.; Kewalramani, T.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Pre-transplant evaluation with both CT and PET following second-line therapy is essential for predicting outcome in patients with transplant-eligible relapsed and primary refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Nimer, S. D.; Zelenetz, A. D.; Kewalramani, T.; Vanak, J. M.; Maragulia, J. C.; Yahalom, J.; Moskowitz, C.
    Blood (2008)

    Fulltext@MSK | Save
  • Rituximab fails to reduce histologic transformation (HT) rate of follicular lymphoma (FL) to diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Marciscano, A. E.; Gupta, N.; Zhang, Z. G.; Teruya-Feldstein, J.; Noy, A.
    Blood (2008)

    Fulltext@MSK | Save
  • Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma
    Meeting Abstract

    Leonard, J. P.; LaCasce, A.; Smith, M. R.; Noy, A.; Yap, J. T.; Van Den Abbeele, A. D.; Yu, J. Q.; Chen-Kiang, S.; Ely, S. A.; Vallabhajosula, S.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors
    Meeting Abstract

    Kurzrock, R.; Hamlin, P.; Gordon, M.; Hong, D.; Fu, S.; Younes, A.; Hannah, A.; Palladino, M. A.; Spear, M. A.; Aghajanian, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Validation of the international harmonization project (IHP) guidelines in early stage Hodgkin lymphoma (HL) treated with adriamycin, vinblastine and gemcitabine (AVG) (CALGB 50203): Early results
    Meeting Abstract

    Kostakoglu, L.; Straus, D. J.; Schoder, H.; LaCasce, A. S.; Bartlett, N. L.; Hall, N.; Johnson, J. L.; Jung, S. H.; Canellos, G. P.; Schwartz, L. H.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Efficacy of extracorporeal photopheresis (ECP) monotherapy in the treatment of cutaneous T cell lymphoma (CTCL)
    Meeting Abstract

    Knobler, R.; Foss, F.; Duvic, M.; Straus, D.; Horwitz, S.; Zain, J.; Kuzel, T.; Querfeld, C.; Campbell, K.; Geskin, L.
    Journal of Investigative Dermatology (2008)

    Fulltext@MSK | Save
  • A phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lympboprolifierative malignancies
    Meeting Abstract

    Horwitz, S. M.; Vose, J. M.; Advani, R.; Sankhala, K.; Padmanabhan, S.; Hamlin, P. A.; Chen, A.; Wilroy, S.; Zain, J. M.; Wright, D.; more...
    Blood (2008)

    Fulltext@MSK | Save